Featured Research

from universities, journals, and other organizations

Viral Vector Delivers Dystrophin Gene To Mouse Muscle

Date:
November 4, 1998
Source:
University Of Michigan
Summary:
University of Michigan scientists have developed a new generation of "gutted" viral vectors that deliver the gene for dystrophin to the muscles of adult mice with muscular dystrophy without triggering their immune systems to attack the foreign virus.

DENVER---University of Michigan scientists have developed a new generation of "gutted" viral vectors that deliver the gene for dystrophin to the muscles of adult mice with muscular dystrophy without triggering their immune systems to attack the foreign virus. The vector is called a "gutted" virus, because it has been stripped of most of its original genes to make room for the large dystrophin gene.

At last year's American Society for Human Genetics meeting, Jeffrey S. Chamberlain, Ph.D., associate professor of human genetics in the U-M Medical School, reported the vector's ability to induce long-term expression of the full-sized dystrophin protein in an immuno-deficient strain of adult mice with Duchenne muscular dystrophy. At this year's meeting, Giovanni Salvatori, Ph.D., post-doctoral research fellow in Chamberlain's lab, reported the same results in mice with a normal immune system.

"Using this new version of our viral vector, we have induced stable production of dystrophin for at least four months in muscle fibers of adult, dystrophic mice with normal immune systems," Salvatori said. "Removing a reporter gene called LacZ from the vector was the key to reducing the vector's strong immunogenic effect. Although we still see a small immune response, it peaks after 30 days and does not appear to adversely affect the ability of mouse muscle to take up the vector and produce dystrophin."

A new cell packaging line, also under development at the U-M, will make it possible to produce large amounts of the vector without contamination by other proteins or viruses that could trigger an immune response in humans, according to Salvatori.

The result is significant, because stability and immune response were two major problems that remained to be solved in mice before the U-M's dystrophin vector could be tested for safety and effectiveness in humans. Chamberlain and Jerry Mendell, M.D., of Ohio State University Medical Center, plan to begin testing the vector for safety in humans in the spring of 1999.

Dystrophin is a protein critical for normal maintenance of muscle tissue. Muscular dystrophy is caused by mutations in a large, complex gene which contains instructions telling muscle cells how to produce dystrophin. Because they lack the genetic code to produce dystrophin, children with muscular dystrophy gradually lose muscle tissue and die of heart or respiratory failure.

For eight years, Chamberlain and his U-M research team have been overcoming technical obstacles to an effective gene therapy treatment for muscular dystrophy. They have focused on using modified adenoviruses---the same type of virus that causes colds---as delivery vehicles, because they have a natural ability to enter muscle cells and deliver the dystrophin gene. Chamberlain is a member of the U-M Department of Human Genetics and also is affiliated with the Center for Gene Therapy in the U-M Health System.

Current collaborators in the U-M program to develop new gene therapy viral vectors for dystrophin include Ph.D. research fellows Catherine Barjot, Catherine Begy, Christiana DelloRusso, Dennis Hartigan-O'Connor, Ann Saulino and Michael Hauser, who is now at Duke University.

The work is funded by the National Institutes of Health, the Muscular Dystrophy Association and a private foundation established by a Birmingham, Mich., couple, Chip and Betsy Erwin, to support the U-M research program.


Story Source:

The above story is based on materials provided by University Of Michigan. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan. "Viral Vector Delivers Dystrophin Gene To Mouse Muscle." ScienceDaily. ScienceDaily, 4 November 1998. <www.sciencedaily.com/releases/1998/10/981031181529.htm>.
University Of Michigan. (1998, November 4). Viral Vector Delivers Dystrophin Gene To Mouse Muscle. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1998/10/981031181529.htm
University Of Michigan. "Viral Vector Delivers Dystrophin Gene To Mouse Muscle." ScienceDaily. www.sciencedaily.com/releases/1998/10/981031181529.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins